ClinConnect ClinConnect Logo

Main Menu

Search for Trials
For HCPs
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT02064972

CEC Count Changes to Support GvHD Diagnosis.

Launched by AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA · Feb 14, 2014

Download PDF Apply for Trial

Trial Information

Current as of April 25, 2025

Completed

Keywords

Graft Vs Host Disease Hematopoietic Stem Cell Transplant Biological Marker Circulating Endothelial Cells Endothelial Dysfunction

ClinConnect Summary

The endothelial damage is a characteristic common to several complications of vascular origin that may occur in the course of allo-HSCT (GVHD, IPS, VOD, TMA). The diagnosis of vascular complications represents an interesting challenge, but unfortunately limited by the fact that the markers of endothelial damage are extremely scarce. In particular, the plasmatic dosage of von Willebrand factor, thrombomodulin and adhesion molecules generated results difficult to use for a potential application for routine diagnostics for the high degree of non-specificity and the potential influence on the a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Patients with hematological disorders undergoing allo-HSCT,
  • • Age 18-65 years.
  • • Sign of written informed consent form at the time of study entry.
  • Exclusion Criteria:
  • • No candidates to allo-HSCT.
  • • Patients under the age of 18 years.

Trial Officials

Camillo Almici, M.D.

Principal Investigator

Transfusion Medicine, Spedali Civili Brescia, Italy

About Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

The Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia is a leading healthcare organization based in Brescia, Italy, dedicated to providing high-quality medical services and promoting clinical research. As a prominent clinical trial sponsor, it focuses on advancing medical knowledge and improving patient care through innovative research initiatives. The institution integrates multidisciplinary expertise and state-of-the-art facilities to facilitate the development of new therapies and treatments, ensuring adherence to rigorous ethical and regulatory standards. With a commitment to enhancing public health, the Azienda plays a pivotal role in fostering collaborations among healthcare professionals, researchers, and industry partners.

Locations

Brescia, , Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials